Lung Cancer Diagnostics - Global Strategic Business Report

The global market for Lung Cancer Diagnostics was valued at US$3.0 Billion in 2024 and is projected to reach US$4.7 Billion by 2030, growing at a CAGR of 7.8% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Lung Cancer Diagnostics market.

Global Lung Cancer Diagnostics Market - Key Trends & Drivers Summarized

What Innovations Are Shaping Lung Cancer Diagnostics?

The lung cancer diagnostics market has witnessed remarkable innovation in recent years, propelled by advancements in medical technology and a deeper understanding of the disease’s molecular biology. Cutting-edge tools such as liquid biopsies, next-generation sequencing (NGS), and AI-powered imaging solutions are reshaping how lung cancer is identified and monitored. Liquid biopsies, which analyze biomarkers in blood, offer a minimally invasive alternative to traditional tissue biopsies, making diagnostics safer and more patient-friendly. NGS has enabled detailed genetic profiling of tumors, allowing for personalized treatment plans that target specific genetic mutations. Additionally, artificial intelligence has become a game-changer, significantly improving the speed and accuracy of diagnostics by analyzing complex imaging data. These innovations are collectively enhancing early detection rates and enabling more effective treatments.

How Is Precision Medicine Transforming The Landscape?

Precision medicine has brought a paradigm shift to the lung cancer diagnostics market by enabling targeted therapies based on individual patient profiles. Advances in biomarker research, such as identifying EGFR mutations and ALK rearrangements, have made targeted diagnostics an essential part of treatment planning. Companion diagnostics are increasingly paired with specific therapies to identify patients likely to benefit from a given treatment. For instance, PD-L1 testing has become critical for immunotherapy decisions. These diagnostic tools are not only enhancing patient outcomes but also reducing healthcare costs by ensuring appropriate treatment regimens are chosen from the start. With pharmaceutical companies heavily investing in research and development, the integration of precision diagnostics into treatment protocols is expected to accelerate further.

Why Are Emerging Economies Driving Market Growth?

While developed regions like North America and Europe dominate the lung cancer diagnostics market due to robust healthcare infrastructure and advanced research capabilities, emerging economies are quickly becoming key players. Rising pollution levels, increasing tobacco consumption, and growing awareness of early cancer detection are fueling demand in countries like China, India, and Brazil. Governments and private organizations are also investing in healthcare infrastructure to improve accessibility and affordability of diagnostics. Telemedicine platforms and mobile diagnostic units are playing a pivotal role in rural outreach, bridging the gap between urban medical hubs and underserved areas. The expanding middle class in these regions, coupled with increased healthcare expenditure, is further driving the adoption of advanced diagnostic technologies.

What Is Driving Growth in the Lung Cancer Diagnostics Market?

The growth in the lung cancer diagnostics market is driven by several factors, including technological advancements, shifting consumer preferences, and evolving clinical practices. Technological breakthroughs, such as AI integration in imaging and the development of highly sensitive liquid biopsy techniques, are transforming how lung cancer is detected and monitored. The increasing focus on early detection, spurred by growing awareness campaigns, is encouraging more individuals to undergo screening, especially in high-risk populations. Furthermore, the rising prevalence of lung cancer due to environmental and lifestyle factors like air pollution and smoking is expanding the demand for diagnostic services. The adoption of precision diagnostics in conjunction with personalized therapies is also fueling market growth, as pharmaceutical collaborations with diagnostic companies yield better-targeted solutions. Finally, expanding access to healthcare services in emerging markets and the growing emphasis on value-based care are creating a fertile environment for further market expansion.

Report Scope

The report analyzes the Lung Cancer Diagnostics market, presented in terms of units. The analysis covers the key segments and geographic regions outlined below.

Segments: Test (Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy, and Other Tests); Type (Non-Small-Cell Lung Cancer (NSCLC), and Small-Cell Lung Cancer (SCLC); and End-Use (Hospital Laboratories, Cancer Research Institutes, and Other End-Uses).

Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Imaging Tests segment, which is expected to reach US$2.3 Billion by 2030 with a CAGR of a 7.4%. The Sputum Cytology segment is also set to grow at 7.8% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $762.0 Million in 2024, and China, forecasted to grow at an impressive 11.3% CAGR to reach $1.1 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Lung Cancer Diagnostics Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Lung Cancer Diagnostics Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Lung Cancer Diagnostics Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Myriad Genetics, Inc., F. Hoffmann-La Roche AG, Biocartis NV, Epigenomics AG, Biodesix, Inc. and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 48 companies featured in this Lung Cancer Diagnostics market report include:

• Myriad Genetics, Inc.
• F. Hoffmann-La Roche AG
• Biocartis NV
• Epigenomics AG
• Biodesix, Inc.
• Exosome Diagnostics, Inc.
• Admera Health
• Dr Lal PathLabs Ltd.
• Guardant Health, Inc.
• Oncimmune Holding PLC
• Blueprint Genetics OY
• CellMax Life, Inc.
• Circulogene
• BGI Genomics Co Ltd.
• Inivata Ltd.

Tariff Impact Analysis: Key Insights for 2025

Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.

The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.

What’s Included in This Edition:

• Tariff-adjusted market forecasts by region and segment
• Analysis of cost and supply chain implications by sourcing and trade exposure
• Strategic insights into geographic shifts

Buyers receive a free July 2025 update with:

• Finalized tariff impacts and new trade agreement effects
• Updated projections reflecting global sourcing and cost shifts
• Expanded country-specific coverage across the industry